Home / Caspase Activators / Cisplatin

Cisplatin

Catalog #: 2251
25 Citations Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
2251/50
Cisplatin | CAS No. 15663-27-1 | Caspase Activators
1 Image
Description: Potent pro-apoptotic anticancer agent; activates caspase-3
Alternative Names: CDDP

Chemical Name: cis-Diaminodichloroplatinum

Product Details
Citations (25)
Reviews
Biological Activity Technical Data Background Product Datasheets Calculators

Biological Activity

Cisplatin is a potent anticancer agent that blocks DNA synthesis. Induces apoptosis via p53-dependent and -independent mechanisms. Inhibits X-linked inhibitor of apoptosis protein (XIAP) expression and activates caspase-3. In certain glioma cell lines, sensitizes cells to TNF-α-induced apoptosis.

Technical Data

M.Wt:
300.05
Formula:
Cl2H6N2Pt
Solubility:
Soluble to 5 mM in water with gentle warming
Storage:
Store at RT
CAS No:
15663-27-1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

  1. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
    Robinson T, Liu J, Vizeacoumar F, Sun T, Maclean N, Egan S, Schimmer A, Datti A, Zacksenhaus E
    PLoS ONE, 2013;8(11):e78641.
  2. Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2

    Sci Rep, 2016;6(0):25650.
  3. Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.
    Seki et al.
    Cancer Chemother.Pharmacol., 2000;45:199
  4. Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells.
    Nomura et al.
    Urol.Oncology, 2004;22:453
  5. Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisp. and tumor necrosis factor α.
    Duan et al.
    Clin.Cancer Res., 2004;10:234

Product Datasheets

COA view current batch
Or select another batch:
View Batch
SDS
Reconstitution Calculator
Molarity Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Molarity Calculator

=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

⚠ WARNING: This product can expose you to chemicals including Cisplatin, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov

Citations for Cisplatin

The citations listed below are publications that use Tocris products. Selected citations for Cisplatin include:

25 Citations: Showing 1 - 10

  1. Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance.
    Authors: Su Et al.
    Oncogene  2019;38:1979
  2. TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC.
    Authors: Xiao Et al.
    Cancers (Basel)  2019;11
  3. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.
    Authors: Chia Et al.
    Nat Commun  2017;8:435
  4. Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma.
    Authors: Florea Et al.
    Oncotarget  2017;8:22876
  5. Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture.
    Authors: Deng Et al.
    J Pharmacol Exp Ther  2017;360:215
  6. TGF-β-Induced Quiescence Mediates Chemoresistance of Tumor-Propagating Cells in Squamous Cell Carcinoma.
    Authors: Brown Et al.
    Cell Stem Cell  2017;21:650
  7. The BTK Inhibitor, Ibrutinib (PCI-32765) Overcomes PacT. Resistance in ABCB1 and ABCC10 Overexpressing Cells and Tumors.
    Authors: Zhang
    Mol Cancer Ther  2017;16(6):1021
  8. Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.
    Authors: Kim Et al.
    BMC Cancer  2016;16:678
  9. Nuclear COMMD1 Is Associated with CDDP Sensitivity in Ovarian Cancer.
    Authors: Fedoseienko Et al.
    PLoS One  2016;11:e0165385
  10. SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2.
    Authors: Sun Et al.
    Korean J Pain  2015;6:e1990
  11. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated PacT. resistance: a preclinical and pharmacokinetic study.
    Authors: Kathawala Et al.
    Oncotarget  2015;6:510
  12. A New Rat Model of Cisplatin-induced Neuropathic Pain.
    Authors: Lin Et al.
    Oncotarget  2015;28:236
  13. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
    Authors: Liu and Kwiatkowski
    Mol Cancer Ther  2015;14:174
  14. Triglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1(low) Monocytes.
    Authors: Saja Et al.
    Cell Death Dis  2015;12:1802
  15. Tolerance to the antinociceptive effects of chronic mor. requires c-Jun N-terminal kinase.
    Authors: Marcus Et al.
    Mol Pain  2015;11:34
  16. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
    Authors: Szabova Et al.
    Cell Rep  2014;9:e95649
  17. Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Authors: Kathawala Et al.
    Int J Oncol  2014;44:1634
  18. Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated PacT. resistance: a preclinical study.
    Authors: Kathawala Et al.
    Mol Cancer Ther  2014;13:714
  19. Optimization of a cisp. model of chemotherapy-induced peripheral neuropathy in mice: use of vitamin C and sodium bicarbonate pretreatments to reduce nephrotoxicity and improve animal health status.
    Authors: Guindon Et al.
    Mol Pain  2014;10:56
  20. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
    Authors: Robinson Et al.
    PLoS One  2013;8:e78641
  21. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following c
    Authors: Guindon Et al.
    Pharmacol Res  2013;67:94
  22. The heterogenic final cell cycle of chicken retinal Lim1 horizontal cells is not regulated by the DNA damage response pathway.
    Authors: Fard Et al.
    Cell Cycle  2013;13:408
  23. The maintenance of cisplatin- and PacT.-induced mechanical and cold allodynia is suppressed by cannabinoid CB? receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.
    Authors: Deng Et al.
    Mol Pain  2012;8:71
  24. A high throughput scintillation proximity imaging assay for protein methyltransferases.
    Authors: Ibáñez Et al.
    Comb Chem High Throughput Screen  2012;15:359
  25. Functional characterization of the 19q12 amplicon in grade III breast cancers.
    Authors: Natrajan Et al.
    Breast Cancer Res  2012;14:R53

FAQs

No product specific FAQs exist for this product, however you may

View all Small Molecule FAQs

Reviews for Cisplatin

There are currently no reviews for this product. Be the first to review Cisplatin and earn rewards!

Have you used Cisplatin?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review
Tocris Bioscience is the leading supplier of novel and exclusive tools for life science research with over 30 years' experience in the industry. Tocris is a Bio-Techne brand.